ABSTRACT
A 45-year-old white woman established on risankizumab self-presented to our service with pustular psoriasis affecting 60% of her body surface area. No history of pustular psoriasis was described in the 22 years that she had been diagnosed with psoriasis. This, to our knowledge, is the first case of paradoxical pustular psoriasis associated with risankizumab.
Subject(s)
Antibodies, Monoclonal/adverse effects , Dermatologic Agents/adverse effects , Interleukin-23 Subunit p19/antagonists & inhibitors , Psoriasis/chemically induced , Cyclosporine/therapeutic use , Dermatologic Agents/therapeutic use , Disease Progression , Female , Humans , Middle Aged , Psoriasis/drug therapy , Psoriasis/pathologySubject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Dermatitis, Atopic/drug therapy , Immunosuppressive Agents/pharmacology , Molluscum Contagiosum/therapy , Molluscum contagiosum virus/immunology , Adult , Antibodies, Monoclonal, Humanized/pharmacology , Cantharidin/pharmacology , Cantharidin/therapeutic use , Cryotherapy , Dermatitis, Atopic/immunology , Drug Resistance, Viral , Drug Substitution , Humans , Imiquimod/pharmacology , Imiquimod/therapeutic use , Immunosuppressive Agents/therapeutic use , Interleukin-4 Receptor alpha Subunit/antagonists & inhibitors , Interleukin-4 Receptor alpha Subunit/immunology , Male , Molluscum Contagiosum/diagnosis , Molluscum Contagiosum/immunology , Molluscum Contagiosum/virology , Molluscum contagiosum virus/isolation & purification , Treatment OutcomeABSTRACT
Shiitake (Lentinula edodes) is the second most commonly consumed mushroom worldwide. The first case of shiitake mushroom flagellate dermatitis was described in Japan in 1977 and it is now being reported in the western world. We describe the first reported case in Ireland.
Subject(s)
Dermatitis/etiology , Dermatomycoses/etiology , Shiitake Mushrooms , Dermatitis/epidemiology , Dermatomycoses/epidemiology , Female , Humans , Ireland/epidemiology , Middle AgedABSTRACT
Alpha-1-antitrypsin deficiency (AATD)-related panniculitis is an extremely rare and underdiagnosed entity, and there is a paucity of data on its treatment. We report two cases of AATD-related panniculitis. The first was a 24-year-old woman with known AATD who presented with painful leg ulcers refractory to treatment with corticosteroids and colchicine. She had a good response to α1-antitrypsin infusions but required dose adjustment due to flares in disease activity. The second case was a 38-year-old woman who presented with painful nodules on the legs refractory to corticosteroid therapy. Laboratory investigations revealed severe AATD. She had an excellent response to colchicine therapy. In both these cases of AATD, panniculitis was the first clinical manifestation of the disease. AATD-related panniculitis may have none of the typical clinical clues for AATD, such as a family history, cirrhosis or emphysema. Early identification may help prevent these complications from developing.
Subject(s)
Colchicine/therapeutic use , Panniculitis/etiology , Tubulin Modulators/therapeutic use , alpha 1-Antitrypsin Deficiency/complications , alpha 1-Antitrypsin/therapeutic use , Adult , Dapsone/therapeutic use , Female , Humans , Infusions, Intravenous , Panniculitis/drug therapy , Panniculitis/pathology , Young AdultSubject(s)
Psoriasis/drug therapy , Skin Diseases, Vesiculobullous/drug therapy , Ustekinumab/therapeutic use , Acitretin/administration & dosage , Acitretin/adverse effects , Acitretin/therapeutic use , Adalimumab/administration & dosage , Adalimumab/adverse effects , Adalimumab/therapeutic use , Aged, 80 and over , Antibodies, Monoclonal, Humanized/therapeutic use , Cyclosporine/administration & dosage , Cyclosporine/therapeutic use , Drug Resistance/physiology , Female , Humans , Immunosuppressive Agents/therapeutic use , Keratolytic Agents/therapeutic use , Methotrexate/administration & dosage , Methotrexate/therapeutic use , Psoriasis/pathology , Skin Diseases, Vesiculobullous/pathology , Treatment Outcome , Ustekinumab/administration & dosageABSTRACT
BACKGROUND: There is a paucity of medical literature describing the role of dermatology inpatient hospital services for patients with severe dermatologic disease. A diminishing number of US hospitals have a dedicated dermatology inpatient service run by dermatologists. OBJECTIVES: To describe the role of a dermatology-run inpatient service in treatment of severe dermatologic disease from 2000 to 2010 at our institution. METHODS: We studied demographic characteristics, indications for admission and length of stay for the adult (age, >18 years) dermatology inpatient hospital service over the most recent decade. We compared data from the first 5.5 years with the subsequent 5.5 years and with previously published data. RESULTS: A total of 1732 patients had 2216 inpatient admissions to the adult service from 2000 to 2010. The mean (SD) age was 61.3 (17.7) years (age range 18-100 years). Median duration of admission was 3 days interquartile range (IQR), 2-5 days. The most common indications for admission were dermatitis (44.2%), psoriasis (17.4%) and cutaneous T-cell lymphoma (9.2%). We compared admissions from 2000 to mid-2005 (n = 1260) to admissions from mid-2005 to 2010 (n = 956). Statistically significant changes included median length of stay (decreased from 4 days [IQR, 3-6 days] to 3 days [IQR, 2-4 days] P < 0.01), admissions for psoriasis (decreased from 20.7% to 13.0%; P < .01) and admissions for dermatitis (increased from 41.6% to 47.6%; P < .01). CONCLUSION: The number of patients admitted and the median length of stay decreased between the 2 periods. Indications for admission have changed significantly across the two time periods.